Posts tagged alzinova
Alzinova's drug substance for the Alzheimer ALZ-101 vaccine is now produced for the upcoming clinical Phase 1b study
Alzinova's drug substance for the Alzheimer ALZ-101 vaccine is now produced for the upcoming clinical Phase 1b study

Alzinova AB has secured materials for the clinical Phase 1b study through the manufacturing of the drug substance for the oligomer-specific vaccine ALZ-101. The high-purity material meets the quality requirements of the clinical trial. The clinical trial with ALZ-101 on Alzheimer's disease patients is expected to start during the second quarter of 2021.

Read More
PressreleaseMelisha Linnellalzinova, vaccin, alzheimers